Rakovina Therapeutics Debentureholders Opt for Shares in Interest Payment

Rakovina Therapeutics Inc ( (TSE:RKV) ) has provided an update.

Rakovina Therapeutics Inc. announced that certain holders of its 12.0% unsecured convertible debentures have opted to receive common shares instead of cash for a portion of the interest payment due on May 29, 2025. This decision affects approximately C$16,740 of the total C$87,240 interest payable, with the remaining amount settled in cash. This move reflects the company’s strategic financial management and may impact its market positioning by potentially increasing its share liquidity. The issuance of shares is contingent upon meeting specific conditions and receiving necessary approvals, including from the TSX Venture Exchange.

More about Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. is a biopharmaceutical research company dedicated to developing innovative cancer treatments. The company leverages unique technologies targeting the DNA-damage response, powered by proprietary generative AI platforms, to accelerate the optimization of drug candidates. Rakovina aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners.

Average Trading Volume: 317,557

Technical Sentiment Signal: Sell

Current Market Cap: C$6.25M

See more data about RKV stock on TipRanks’ Stock Analysis page.